Carregant...
Docetaxel-Related Toxicity in Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer
BACKGROUND: Docetaxel plus androgen deprivation therapy (ADT) offers a survival benefit in metastatic hormone-sensitive prostate cancer (mHSPC). However, one trial evaluating docetaxel in mHSPC (GETUG-AFU15) showed unexpected toxicity; raising concerns that docetaxel may carry increased toxicity whe...
Guardat en:
| Publicat a: | Med Oncol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5298886/ https://ncbi.nlm.nih.gov/pubmed/27300548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-016-0793-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|